Rapid testing saves lives.

Building a better tomorrow

About Us

Diagnostic Ventures is proud to work with leading PhD researchers at Brigham Young University. Our technology has been in development since 2016 and currently targets the identification of sepsis-causing pathogens within 20 minutes without a blood culture.

Originally funded by a $5.2M grant from the National Institute of Health.

This product is under development and not approved for sale. This product is not yet FDA approved.

Our Solution

Centrifugal Pathogen Isolation


1. Zanotti-Cavazzoni S. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock.  Yearbook of Critical Care Medicine. 2007; 2007:187-188. doi:10.1016/s0734-3299(08)70339-3.

2. Global Sepsis Alliance, 2024

3. Rudd et al. Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study, 2020.